Literature DB >> 23536401

Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Laura Barrado1, Patricia Brañas, M Ángeles Orellana, M Teresa Martínez, Gloria García, Joaquín R Otero, Fernando Chaves.   

Abstract

Multilocus sequence typing and nrdA sequence analysis identified 6 different species or genogroups and 13 sequence types (STs) among 15 Achromobacter isolates from cystic fibrosis (CF) patients and 7 species or genogroups and 11 STs among 11 isolates from non-CF patients. Achromobacter xylosoxidans was the most frequently isolated species among CF patients.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23536401      PMCID： PMC3716108          DOI： 10.1128/JCM.00494-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-{beta}-lactamase from different Italian hospitals.

Authors:  Maria Letizia Riccio; Lucia Pallecchi; Jean-Denis Docquier; Stefania Cresti; Maria Rosaria Catania; Laura Pagani; Cristina Lagatolla; Giuseppe Cornaglia; Roberta Fontana; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.

Authors:  Frans De Baets; Petra Schelstraete; Sabine Van Daele; Filomeen Haerynck; Mario Vaneechoutte
Journal:  J Cyst Fibros       Date:  2006-06-21       Impact factor: 5.482

3.  Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation.

Authors:  D Moissenet; A Baculard; M Valcin; V Marchand; G Tournier; A Garbarg-Chenon; H Vu-Thien
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

4.  Identification and distribution of Achromobacter species in cystic fibrosis.

Authors:  Theodore Spilker; Peter Vandamme; John J Lipuma
Journal:  J Cyst Fibros       Date:  2012-11-07       Impact factor: 5.482

5.  Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis.

Authors:  J W Krzewinski; C D Nguyen; J M Foster; J L Burns
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

6.  Prospective evaluation of emerging bacteria in cystic fibrosis.

Authors:  G Steinkamp; B Wiedemann; E Rietschel; A Krahl; J Gielen; H Bärmeier; F Ratjen
Journal:  J Cyst Fibros       Date:  2005-03       Impact factor: 5.482

7.  Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.

Authors:  Yohei Doi; Laurent Poirel; David L Paterson; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

8.  Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Authors:  Samiya Razvi; Lynne Quittell; Ase Sewall; Hebe Quinton; Bruce Marshall; Lisa Saiman
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410

9.  Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.

Authors:  Tiziana Raso; Ornella Bianco; Bianca Grosso; Mario Zucca; Dianella Savoia
Journal:  APMIS       Date:  2008-09       Impact factor: 3.205

10.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079
View more
  15 in total

1.  AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.

Authors:  Pisut Pongchaikul; Pitak Santanirand; Svetlana Antonyuk; Craig Winstanley; Alistair C Darby
Journal:  FEMS Microbiol Lett       Date:  2020-07-01       Impact factor: 2.742

2.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

3.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

4.  Distribution of Achromobacter Species in 12 French Cystic Fibrosis Centers in 2020 by a Retrospective MALDI-TOF MS Spectrum Analysis.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Anaïs Folletet; Julien Bador; Maryam Abid; Marlène Amara; Clémence Beauruelle; Olivier Belmonte; Pierre Boyer; Emilie Cardot-Martin; Anne-Gaëlle Cauchie; Sylvie Colin de Verdière; Claire Daurel; Cécile Gaudru; Farida Hamdad; Geneviève Héry-Arnaud; Baptiste Hoellinger; Claudie Lamoureux; Marie-Frédérique Lartigue; Damasie Malandain; Océane Marchand; Caroline Piau; Sandrine Picot; Hélène Revillet; Zeina Sabouni; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2022-05-05       Impact factor: 11.677

5.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

6.  Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients.

Authors:  Ijeoma N Okoliegbe; Karolin Hijazi; Kim Cooper; Corinne Ironside; Ian M Gould
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples.

Authors:  L Amoureux; J Bador; T Verrier; H Mjahed; C DE Curraize; C Neuwirth
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

8.  Genotypic and phenotypic applications for the differentiation and species-level identification of achromobacter for clinical diagnoses.

Authors:  Margarita Gomila; Claudia Prince-Manzano; Liselott Svensson-Stadler; Antonio Busquets; Marcel Erhard; Deny L Martínez; Jorge Lalucat; Edward R B Moore
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

9.  Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.

Authors:  M C Firmida; R H V Pereira; E A S R Silva; E A Marques; A J Lopes
Journal:  Braz J Med Biol Res       Date:  2016-02-23       Impact factor: 2.590

10.  Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Rapid Detection of Isolates Belonging to the Epidemic Clones Achromobacter xylosoxidans ST137 and Achromobacter ruhlandii DES from Cystic Fibrosis Patients.

Authors:  Thomas Garrigos; Manon Dollat; Arnaud Magallon; Angélique Chapuis; Véronique Varin; Julien Bador; Nadia Makki; Lise Cremet; Elise Persyn; Emilie Cardot-Martin; Fedoua Echahidi; Charlotte Peeters; Denis Pierard; Peter Vandamme; Alexia Verroken; Catherine Neuwirth; Lucie Amoureux
Journal:  J Clin Microbiol       Date:  2021-08-04       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.